Vinorelbine-induced regression of a choroidal metastasis from primary breast carcinoma

• Main Authors: Malvika Arya, Jay S. Duker
• Format: Article
• Language: English
• Published: BMC 2018-05-01
• Series: International Journal of Retina and Vitreous
• Subjects: Choroidal neoplasm; Uveal neoplasm; Breast cancer; Vinorelbine; Antineoplastic agents phytogenic; Chemotherapeutic anticancer agents
• Online Access: http://link.springer.com/article/10.1186/s40942-018-0121-3

Abstract Background Various therapeutic options exist to treat choroidal metastatic lesions. However, they are all associated with potential long-term adverse effects. This case report discusses a case of choroidal metastasis from primary breast carcinoma that regressed after single-agent chemotherapy. Case presentation We report a case of choroidal metastasis from estrogen receptor (ER) positive breast carcinoma that became resistant to endocrine therapy. The primary malignancy was treated with surgical resection and adjuvant chemoradiation, followed by hormone therapy with various agents in combination with kinase inhibitors for ER resistance. The choroidal metastatic lesion regressed after the initiation of vinorelbine. Vinorelbine is a cytotoxic vinca alkaloid with tolerable systemic adverse effects. Conclusions This case report highlights the possible role of vinorelbine as a single chemotherapeutic agent for the conservative therapy of uveal metastasis from advanced breast carcinoma, irrespective of responsiveness to hormone therapy.